Obesity jab drug fails to slow Alzheimer's
Summary
Drug maker Novo Nordisk conducted trials to see if semaglutide, an ingredient in a weight loss drug, could slow Alzheimer's disease. The trials with over 3,800 participants showed the drug had no effect on Alzheimer's progression compared to a placebo. Results will be discussed at an upcoming Alzheimer's conference and are not yet peer-reviewed.Key Facts
- Novo Nordisk tested semaglutide, an ingredient in Wegovy, for Alzheimer's disease.
- Over 3,800 people with mild cognitive impairment participated in the trials.
- The drug is already used for type 2 diabetes and obesity.
- Trials showed semaglutide did not affect Alzheimer's progression compared to a placebo.
- Results will be presented at an Alzheimer's conference and are not yet published in a scientific journal.
- The trials highlighted the complexity of Alzheimer's, which involves multiple biological processes.
- Other Alzheimer's drugs are also in clinical trials, with over 130 currently under investigation.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.